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Introduction
Bortezomib (codenamed as PS-341 and marketed as Velcade 
by Millennium Pharmaceuticals) was developed as a potent, 
specific proteasome inhibitor for the treatment of relapsed and 
refractory multiple myeloma1 and currently it is still one of the 
most effective drugs currently available for treating multiple 
myeloma. While bortezomib alone achieved a 40% response 
rate (RR), the RR was further improved to 88% in combination 
with dexamethasone2. However, only 4 of 15 patients with acute 
leukemia showed a decrease in blast count3. Bortezomib has also 
shown poor efficacy in the treatment of chronic lymphocytic 
leukemia (CLL), despite potent in vitro activity4,5. Recently, it 
was found that some of dietary flavonoids and vitamin C have 
antagonistic interaction with bortezomib which affects the anti-
cancer property of this drug6-9. According to that 77% of patients 
use vitamins or herbs concurrently with conventional anticancer 
treatment10, here we review current knowledge concerning how 
dietary intake could counteract chemotherapy with bortezomib. 
Chemical structure and anti-cancer 
properties of bortezomib
Bortezomib is a modified dipeptidyl boronic acid. The product is 
provided as a mannitol boronic ester which, in reconstituted form, 
consists of the mannitol ester in equilibrium with its hydrolysis 
product, the monomeric boronic acid (Figure 1). One of the 
first proteasome inhibitors synthesized was MG-132, a peptide 
aldehyde based on calpain inhibitor I11. However, MG-132 was 
found to be nonselective because it inhibits other enzymes. 
Using a boronic acid instead of an aldehyde circumvents theses 
hortcomings and provides a measure of selective proteasome 
inhibition relative to many other serine proteases2,12.
Previous studies suggested that proteasome inhibition 
by bortezomib kills multiple myeloma cells via blocking 
inducible I-κB degradation and consequently NF-κB activation 
implicated as one of the mechanisms of tumor cell resistance to 
apoptosis1,13,14. It induces cell cycle arrest and apoptosis in small 
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AbstrAct Eat more ‘green’ or eat ‘five a day’ is one of the most important healthy lifestyle behaviours in the 21 century. Aiming to 
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cancer cells by preventing degradation of p21/waf1, a cyclin-
dependent kinase inhibitor 1, and p5315. In vitro experiment 
demonstrated that bortezomib also prevents degradation of Bax, 
a short-lived pro-apoptotic protein, in CLL and diffuse large 
B-cell lymphoma (DLBCL) cells16. Malignant cells can resist by 
failing to accumulate pro-apoptotic proteins after bortezomib 
treatment, and/or increase the levels of anti-apoptotic proteins, 
inducing autophagy to clear up damaged proteins17.
Chemical structure and classification of 
flavonoids
Flavonoids are biologically active polyphenolic compounds 
with various health benefits, ubiquitously found in fruits, 
vegetables, tea, and wine. Flavonoids are benzo-γ-pyrone 
derivatives consisting of phenolic and pyrane rings (Figure 2) 
and are classif ied according to substitutions, including 
flavonols (e.g., quercetin, kaempferol), flavones (e.g., apigenin, 
luteolin), flavanones (e.g., hesperidin, naringenin), flavan-3-
ols (e.g., catechin, theaflavin, and gallic esters of catechin and 
theaflavins), anthocyanidins (e.g., pelargonidin, cyanidin), 
and isoflavones (e.g., genistein, daidzein)18,19. They also have 
different distribution of hydroxyl groups (-OH) in their B ring. 
For example, quercetin is a catechol with 2 hydroxyl groups 
(-OH) on neighbouring carbon atoms of their B rings; and 
myricetin, a pyrogallol, has 3-OH groups, whereas both apigenin 
and kaempferol have only one isolated -OH group on the B 
ring (Figure 3A). There are many flavonoids containing either 
catechol or pyrogallol structures in human food sources, such 
as green vegetables, green tea and fruits (Table 1). Interestingly, 
Figure 1 Basic chemical structures of bortezomib (A) and MG-132 or 
MG-262 (B).
Figure 2 Basic chemical structure of flavonoids.
Figure 3 A. Chemical structure of quercetin, myricetin, kaempferol, 
and apigenin. The B-rings of quercetin and myricetin are catechol 
and pyrogallo respectively. B. Chemical structure of vitamin C or 
ascorbic acid.
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vitamin C (L-ascorbic acid), an analogue of catechol, contains 
a vicinal diol group or two neighbouring hydroxyl groups 
(Figure 3B). The hydroxyl configuration on the B-ring of 
flavonoids and in the vicinal diol group of vitamin C is the 
most significant determinant of scavenging of reactive oxidative 
species (ROS)18,20,21. Hydroxyl groups on the B-ring donate 
hydrogen and an electron to hydroxyl, peroxyl, and peroxynitrite 
radicals, stabilizing them and giving rise to a relatively stable 
flavonoid radical18. However, the complex formation of the 
vicinal diol in catechol and vitamin C and its simple derivatives 
with boron acid in aqueous solution has been well characterized 
chemically for several decades8,20. 
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Flavonoids quercetin and myricetin 
diminish the anti-cancer effects of 
bortezomib
Bortezomib does not kill leukemic cells in vivo, despite its potent 
cytotoxicity in vitro4. To mimic in vivo environment, Liu et al.8 
found that the efficacy of bortezomib dramatically compromised 
when CLL cells were cultured in 50% fresh human plasma 
compared to culturing in 10% fetal calf serum, suspecting that 
unknown antagonistic compounds against bortezomib exist 
in the blood. Quercetin is one of the abundant flavonol-type 
flavonoids, commonly found in green leaves of vegetables and 
fruits. The average daily intake of flavonoids (quercetin, myricetin, 
kaempferol) and two other flavone-type flavonoids (apigenin 
and luteolin), was estimated to be 23 mg/day, with quercetin 
(mean intake, 16 mg/day) as the most consumed of these five 
flavonoids22. Quercetin is rich in the plasma and is extensively 
plasma-bound, almost exclusively to human serum albumin23. 
The plasma concentration of quercetin is tightly associated with 
its dietary intake24. Quercetin has many functional similarities 
to bortezomib in the treatment of cancer cells, such as inhibiting 
proteasome and NF-κB, inducing apoptosis and cell cycle arrest 
(Table 2). However, when treating CLL cells with quercetin 
and bortezomib simultaneously, the apoptosis-inducing effects 
of both compounds were vanished completely8. It was thought 
that quercetin-mediated antagonism on bortezomib was due to 
inhibition of ROS generation. N-acetylcysteine, a ROS scavenger, 
failed to inhibit bortezomib-induced cells death, instead enhanced 
its cytotoxicity. A similar result was produced by another group7. 
The boronic acid group, -B(OH)2, which is present in bortezomib, 
can be expected to form cyclic boronate esters with the catechols 
and pyrogallols groups (Figure 4A), but not with flavonoids such 
as apigenin and kaempferol in which pairs of adjacent hydroxyl 
groups are absent (Figure 3A). Using Roman spectrophotometry, 
Liu et al., confirmed the directly chemical binding between 
quercetin and bortezomib (Figure 4B). 
As expected, myricetin showed a similar blocking effect on 
bortezomib-induced apoptosis as quercetin did but neither 
apigenin nor kaempferol interfered with bortezomib. The 
inhibitory effects of plasma on bortezomib cannot be attributed 
solely to quercetin as its reported peak serum concentration 
after a supplemental diet is too low32. However, there are many 
dietary flavonoids that have similar structures with quercetin 
or myricetin (Table 1), so the intake of dietary flavonoids may 
Table 1 Dietary flavonoids with catechol and pyrogallol structures
Catechols or pyrocatechols Nature sources Pyrogallols Nature sources
Quercetin Fruits, vegetables, green tea, red wine Myricetin Fruits, vegetables and herbs
Catechin Green tea Gallic acid Tea
Epicatechin (EC) Green tea Gallocatechin (GC) Green tea
Epicatechin gallate (ECG) Green tea Epigallocatechin (EGC) Green tea
Caffeic acid Coffee, fruits, vegetables and herbs Epicatechin gallate (ECG) Green tea
Rutin Buckwheat Epigallocatechin gallate (EGCG) Green tea
Luteolin Fruits, vegetables Tannin Tea, wine, fruits, and chocolates 
Cyanidin Color of fruits Delphinidin Color of fruits
Table 2 Comparison of apoptosis-inducing effects of quercetin and bortezomib
Property Quercetin Bortezomib References
Compound Flavonoid Boronic dipeptide Adams et al.2; Boulton et al.23
Proteasome binding site Inhibition on β5 subunit Inhibition on β5 subunit Chen et al.25
ROS Inhibition Generation Perez-Galan et al.26
NF-κB Inhibition Inhibition Dias et al.27
Bax Activation Activation Chen et al.25; Dias et al.27
Caspase-3 Activation Activation Choi et al.28; Yu et al.29
Cell cycle G2/M arrest G2/M arrest Yang et al.
30; Yin et al.31
Proliferation Inhibition Inhibition Yang et al.30; Yin et al.31
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reduce the killing activity of bortezomib on circulating leukemic 
cells by the formation of a boronate complex.
This study confirmed that the apoptotic effect of MG-262, a 
boron acid-containing proteasome inhibitor (Figure 1B), can 
also be diminished by quercetin. By contrast, the cytotoxic effect 
of MG-132 which does not contain boron acid was not affected 
by quercetin. Importantly, to neutralize flavonoids, inorganic 
boric acid was added into autologous plasma before treatment 
with bortezomib. In a non-cytotoxic dose range, boric acid 
restored apoptosis-inducing activity of bortezomib in a dose-
dependent manner8.
Flavonoids in green tea block anti-cancer 
effect of bortezomib and other boronic 
acid-based proteasome inhibitor
The health benefits and cancer prevention/anti-cancer effects 
of green tea components have drawn great attention for over 
two decades due to their anti-oxidant property33-36. The anti-
oxidant compounds in green tea, including Gallocatechin 
(GC), Epigallocatechin (EGC), Epicatechin gallate (ECG), 
and Epigallocatechin gallate (EGCG), are pyrogallo-based 
compounds and EGC contains extra catechol ring (Figure 5). 
Figure 4 A. Complex formation between catechol derivatives 
and boronic acid to form boronate ester. B. Detection of 
chemical reactive between bortezomib and quercetin by Raman 
Spectrophotometry.
Figure 5 Chemical structures of green tea compounds.
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EGCG, the most bioactive green tea polyphenol has been 
proposed as a multi-functional chemoprevention and anti-cancer 
agent33,37-40.
Golden et al.6 initially found that 10 µM of EGCG completely 
blocked 10 nM bortezomib-induced apoptosis in primary and 
multiple myeloma cell lines, and also in glioblastoma cell lines. 
EGCG from drug store, called TEA-VIGO, produced similar 
results on blocking bortezomib as the chemical from Sigma. 
Other green tea polyphenol components, including EGC, ECG, 
and EC, all showed blocking effects on bortezomib but required 
relatively higher concentrations. Complete green tea extract 
(GTE) also blocked the killing by bortezomib regardless the 
cytotoxic effect of GTE alone at higher concentration. Similar 
to the study Liu et al.8, Golden et al., also tested the antagonistic 
effect of EGCG on other proteasome inhibitors which either 
contain boronic acid such as Nelfinavir, PS-1 and MG-132 or 
without it, such as MG-262 and PX-1X. They found that the 
protective feature of EGCG is not a general effect toward all 
proteasome inhibitors, but rather displays selectivity toward 
those compounds harboring a boronic acid moiety. For in vivo 
study, multiple myeloma cells were implanted subcutaneously 
into nude mice and, after sizable tumors had formed, the animals 
received treatment with both bortezomib and/or EGCG. In 
tumors from animals treated with EGCG (25 to 50 mg/kg) or 
EGCG plus bortezomib, there is no increase of apoptotic cells 
compared with tumors from untreated controls. Finally, using 
1H NMR and 1C NMR techniques they confirmed that direct 
interaction between EGCG and bortezomib lead to formation of 
a covalent cyclic boronate between these two compounds6. 
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Vitamin C inhibits anti-cancer effect of 
bortezomib
Vitamin C or L-ascorbic acid is the most common healthy 
food supplement for both normal human being and cancer 
patients. Structurally, it is not a flavonoid, or polyphenol but 
it contains a vicinal diol (Figure 3B) and has a strong anti-
oxidant activity. Currently, the effect of vitamin C in cancer 
prevention and influence on chemotherapeutic drugs remain 
controversial41-43. 
Perrone et al.9 observed that vitamin C blocks bortezomib-
mediated growth inhibition, accumulation of ubiquitinated 
proteins and inhibition of proteasome activity in multiple 
myeloma cell lines. This antagonistic effect of vitamin C on 
bortezomib is limited to peptide boronic class proteasome 
inhibitors. This group conducted in vivo study in xenograft 
mouse model of human multiple myeloma by treating mice with 
vitamin C or bortezomib alone or in combination. Bortezomib 
alone significantly inhibited tumor growth while vitamin C 
alone showed no effect. Importantly, vitamin C (40 mg/kg/day) 
completely blocked bortezomib-mediated anti-cancer effect.
Effects of non-vicinal diol containing 
naturally occurring compounds on 
bortezomib
Previous study by Liu et al.8, demonstrated that non-vicinal diol 
containing flavonoids such as kaempferol or apignin don’t have 
antagonistic effect on bortezomib. Flavopiridol is a synthetic 
flavonoid based on an extract from an Indian plant for the 
potential treatment of cancer. It was found that flavopiridol 
(Alvacidib) has synergistic effect on bortezomib-induced killing 
in chronic myeloid leukemia44. A phase I study showed that 
bortezomib/flavopiridol regimen appears active in patients with 
relapsed and/or refractory multiple myeloma or non-Hodgkin’s 
lymphoma45. Curcumin is a natural occurring flavonoid extracted 
from Indian spice turmeric. It was found that curcumin and its 
analogs enhanced bortezomib-induced apoptosis in multiple 
myeloma cells46,47. Resveratrol, a nature phenol, is produced by 
Japanese knotweed, red grapes, berries, and peanuts and is also 
found at high concentration in red wine. It was reported that 
resveratrol mediates apoptosis in multiple myeloma cells when 
used alone or in combination with paclitaxel48 or bortezomib49. 
However, a phase II study of SRT501 (a micronized oral 
formulation of resveratrol) with bortezomib found that SRT501 
causes renal failure and minimal efficacy in patients with 
relapsed/refractory multiple myeloma when used alone or in 
combination with bortezomib50.
Preclinical in vivo studies and controversies
A preclinical study on the antagonistic effect of EGCG or 
vitamin C in the anti-tumor activity of bortezomib was 
conducted by Millennium Pharmaceuticals using CWR22 
human prostate xenograft tumors51. Experiment using multiple 
myeloma cell line RPMI8226 showed that the concentration 
of EGCG required for partially inhibiting bortezomib was 
≥11 µM, higher than previously reported, e.g., 10 µM for 
complete inhibition6. The plasma concentrations of EGCG were 
monitored after intravenous (IV) administration of EGCG. 
Single-agent bortezomib 0.8 mg/kg IV demonstrated a tumor 
growth inhibition (TGI) of 53.9%-58.9% versus the control 
group in CWR22 xenograft-bearing mice. EGCG 50 mg/kg 
IV administered two min prior to bortezomib 0.8 mg/kg IV 
resulted in no antitumor activity, demonstrating antagonism 
between EGCG and bortezomib when EGCG levels were 
>200 µM at the time of bortezomib dosing. Pharmacodynamic 
studies were conducted to determine whether EGCG showed 
a concentration-dependent ability to antagonize bortezomib-
induced proteasome inhibition in blood or tumor tissue. 
Four hours after IV administration of bortezomib 0.8 mg/kg, 
mean 20S proteasome inhibition was 44% in blood and 52% 
in tumor. This proteasome inhibition was blunted by the 
combination of EGCG 50 mg/kg IV followed 2 min later by 
bortezomib 0.8 mg/kg IV, which resulted in only 25% and 33% 
proteasome inhibition in blood and tumor, respectively, at 4 h 
post-administration. Golden et al., found that 25 or 50 mg/mL 
EGCG blocked the apoptosis-inducing effect of 0.5 mg/mL 
of bortezomib in nude mice. These results indicate partial or 
complete antagonism of proteasome inhibition by IV dosing of 
EGCG, which is further reflected in the analysis of downstream 
pharmacodynamic markers and ultimately in the antagonism of 
antitumor activity in this combination regimen. 
This group also determined the antagonistic effect of vitamin 
C on bortezomib.Ascorbic acid 40 or 500 mg/kg alone did not 
exhibit any antitumor activity, while bortezomib 0.8 mg/kg IV 
alone had significant antitumor activity compared with controls. 
Surprisingly, they found that ascorbic acid 40 or 500 mg/kg 
in combination with bortezomib also exhibited significant 
antitumor activity compared with controls. No antagonism 
was seen between ascorbic acid and bortezomib in any of the 
combination groups. This is contradicted with previous study 
by Perrone et al.9, which demonstrated that 40 mg/kg ascorbic 
acid abolished 0.1 mg/kg bortezomib-induced tumor growth 
inhibition in human multiple myeloma xenograft-bearing mice. 
It remains unexplained why different xenograft animal models 
and different ratios of drugs produce different results. 
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This study51 concluded that plasma concentrations of EGCG 
and ascorbic acid reported in human subjects taking EGCG or 
vitamin C supplements show no antagonism to the antitumor 
activity of bortezomib in human prostate tumor fragment 
xenograft-bearing mice, and therefore there appears no need for 
patients receiving bortezomib therapy to avoid normal dietary 
consumption of green tea, vitamin C-containing foods, or EGCG 
or vitamin C dietary supplements. 
Unanswered questions and perspectives
Although the direct in vitro interaction between vicinal diol in 
flavonoids/vitamin C and boronic acid was detected by several 
groups6-8, the differential interaction potential in plasma and 
solid tumor environment was not determined. It is still unclear 
why bortezomib can kill malignant cells in the tissue and bone 
marrow but not in the blood. If the anti-cancer property of 
bortezomib is affected by flavonoids in the blood, how it can 
reach to the tumor or bone marrow sites unaffected? 
Some natural products or antioxidants such as luteolin, ellagic 
acid, flavonoids, protocatechuic acid, rosmarinic acid, phenethyl 
caffeate and catechin from vegetables, fruits or herbs have one 
or more vicinal diol groups. Thus these agents may have the 
potential to chemically interact with bortezomib and antagonize 
its activity20. Nonetheless, these studies serve as an always timely 
reminder for healthcare providers of the importance of eliciting 
a complete history from patients and their families, including 
concomitant medications and over-the-counter supplements52. 
It is reasonable to suggest to patients that there are potentially 
negative interactions between proven anticancer therapies 
and ‘complementary’ therapies. Until we, as researchers and 
clinicians, have a clear understanding of the potential interactions 
or lack thereof, we should caution our patients to limit their use 
to maximize their benefit from treatment20. 
There are several strategies which may allow further 
development of proteasome inhibitors for the treatment of 
leukemia8,53. First, decreasing plasma flavonoid concentrations by 
dietary manipulation may, if achievable, be of value in enhancing 
in vivo toxicity of bortezomib. Second, the observation that 
boric acid can compete with the reaction between quercetin 
and bortezomib raises the possibility that the blocking effect of 
flavonoids may be neutralized prior to bortezomib treatment. A 
third option would be to explore the possible therapeutic use of 
proteasome inhibitors which lack a boronate moiety. 
Conflict of interest statement
No potential conflicts of interest are disclosed.
References
1. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, 
Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, 
induces apoptosis, and overcomes drug resistance in human 
multiple myeloma cells. Cancer Res 2001;61:3071-3076.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, 
Lazarus DD, et al. Proteasome inhibitors: a novel class of potent 
and effective antitumor agents. Cancer Res 1999;59:2615-2622.
3. Zhang J, Shen L, Wang J, Luo P, Hu Y. Design, Synthesis and 
Biological Evaluation of Novel Non-Peptide Boronic Acid 
Derivatives as Proteasome Inhibitors. Med Chem 2013. [Epub 
ahead of print].
4. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O’Brien S, et al. 
Phase II study of single-agent bortezomib for the treatment of 
patients with fludarabine-refractory B-cell chronic lymphocytic 
leukemia. Cancer 2006;107:916-924.
5. Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, 
McConkey D. The proteasome inhibitor NPI-0052 is a more 
effective inducer of apoptosis than bortezomib in lymphocytes 
from patients with chronic lymphocytic leukemia. Mol Cancer 
Ther 2006;5:1836-1843.
6. Golden EB, Lam PY, Kardosh A, Gaffney KJ, Cadenas E, Louie 
SG, et al. Green tea polyphenols block the anticancer effects of 
bortezomib and other boronic acid-based proteasome inhibitors. 
Blood 2009;113:5927-5937.
7. Kim TY, Park J, Oh B, Min HJ, Jeong TS, Lee JH, et al. Natural 
polyphenols antagonize the antimyeloma activity of proteasome 
inhibitor bortezomib by direct chemical interaction. Br J Haematol 
2009;146:270-281.
8. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben 
JG, et al. Dietary flavonoids inhibit the anticancer effects of the 
proteasome inhibitor bortezomib. Blood 2008;112:3835-3846.
9. Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun 
G, et al. Ascorbic acid inhibits antitumor activity of bortezomib in 
vivo. Leukemia 2009;23:1679-1686.
10. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary 
SE. Complementary/alternative medicine use in a comprehensive 
cancer center and the implications for oncology. J Clin Oncol 
2000;18:2505-2514.
11. Tsubuki S, Kawasaki H, Saito Y, Miyashita N, Inomata M, 
Kawashima S. Purification and characterization of a Z-Leu-
Leu-Leu-MCA degrading protease expected to regulate neurite 
formation: a novel catalytic activity in proteasome. Biochem 
Biophys Res Commun 1993;196:1195-1201.
12. Adams J. The development of proteasome inhibitors as anticancer 
drugs. Cancer Cell 2004;5:417-421.
13. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima 
212 Jia et al. Why bortezomib cannot go with ‘green’?
T, Richardson P, et al. Combination of proteasome inhibitors 
bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity 
in multiple myeloma. Blood 2008;111:1654-1664.
14. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano 
C, et al. The proteasome inhibitor PS-341 markedly enhances 
sensitivity of multiple myeloma tumor cells to chemotherapeutic 
agents. Clin Cancer Res 2003;9:1136-1144.
15. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H. 
Proteasome inhibitor PS-341 induces growth arrest and apoptosis 
of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 
signaling. Cancer Sci 2004;95:176-180.
16. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC, et 
al. Bortezomib blocks Bax degradation in malignant B cells during 
treatment with TRAIL. Blood 2008;111:2797-2805.
17. Jia L, Gopinathan G, Sukumar JT, Gribben JG. Blocking autophagy 
prevents bortezomib-induced NF-κB activation by reducing I-κBα 
degradation in lymphoma cells. PLoS One 2012;7:e32584.
18. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: 
chemistry, metabolism and structure-activity relationships. J Nutr 
Biochem 2002;13:572-584.
19. Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a 
review of the evidence. J Nutr Gerontol Geriatr 2012;31:206-238.
20. Harvey RD, Nettles J, Wang B, Sun SY, Lonial S. Commentary on 
Perrone et al.: ‘vitamin C: not for breakfast anymore...if you have 
myeloma’. Leukemia 2009;23:1939-1940.
21. Sekher Pannala A, Chan TS, O’Brien PJ, Rice-Evans CA. Flavonoid 
B-ring chemistry and antioxidant activity: fast reaction kinetics. 
Biochem Biophys Res Commun 2001;282:1161-1168.
22. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. 
Dietary antioxidant flavonoids and risk of coronary heart disease: 
the Zutphen Elderly Study. Lancet 1993;342:1007-1011.
23. Boulton DW, Walle UK, Walle T. Extensive binding of the 
bioflavonoid quercetin to human plasma proteins. J Pharm 
Pharmacol 1998;50:243-249.
24. Mullen W, Boitier A, Stewart AJ, Crozier A. Flavonoid metabolites 
in human plasma and urine after the consumption of red onions: 
analysis by liquid chromatography with photodiode array and 
full scan tandem mass spectrometric detection. J Chromatogr A 
2004;1058:163-168.
25. Chen D, Daniel KG, Chen MS, Kuhn DJ, Landis-Piwowar 
KR, Dou QP. Dietary flavonoids as proteasome inhibitors and 
apoptosis inducers in human leukemia cells. Biochem Pharmacol 
2005;69:1421-1432.
26. Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, 
Colomer D. The proteasome inhibitor bortezomib induces 
apoptosis in mantle-cell lymphoma through generation of 
ROS and Noxa activation independent of p53 status. Blood 
2006;107:257-264.
27. Dias AS, Porawski M, Alonso M, Marroni N, Collado PS, 
González-Gallego J. Quercetin decreases oxidative stress, 
NF-kappaB activation, and iNOS overexpression in liver of 
streptozotocin-induced diabetic rats. J Nutr 2005;135:2299-2304.
28. Choi YJ, Jeong YJ, Lee YJ, Kwon HM, Kang YH. (-)
Epigallocatechin gallate and quercetin enhance survival signaling 
in response to oxidant-induced human endothelial apoptosis. J 
Nutr 2005;135:707-713.
29. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response 
to the proteasome inhibitor Bortezomib [VELCADE, PS-341] 
in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol 
Ther 2003;2:694-699.
30. Yang JH, Hsia TC, Kuo HM, Chao PD, Chou CC, Wei YH, et al. 
Inhibition of lung cancer cell growth by quercetin glucuronides 
via G2/M arrest and induction of apoptosis. Drug Metab Dispos 
2006;34:296-304.
31. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, et al. 
Proteasome inhibitor PS-341 causes cell growth arrest and 
apoptosis in human glioblastoma multiforme (GBM). Oncogene 
2005;24:344-354.
32. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB. 
Bioavailability of the dietary antioxidant flavonol quercetin in man. 
Cancer Lett 1997;114:139-140.
33. Agarwal R, Katiyar SK, Zaidi SI, Mukhtar H. Inhibition of 
skin tumor promoter-caused induction of epidermal ornithine 
decarboxylase in SENCAR mice by polyphenolic fraction isolated 
from green tea and its individual epicatechin derivatives. Cancer 
Res 1992;52:3582-3588.
34. Fujiki H, Yoshizawa S, Horiuchi T, Suganuma M, Yatsunami J, 
Nishiwaki S, et al. Anticarcinogenic effects of (-)-epigallocatechin 
gallate. Prev Med 1992;21:503-509.
35. Katiyar SK, Agarwal R, Mukhtar H. Green tea in chemoprevention 
of cancer. Compr Ther 1992;18:3-8.
36. Wang ZY, Huang MT, Ferraro T, Wong CQ, Lou YR, Reuhl K, et al. 
Inhibitory effect of green tea in the drinking water on tumorigenesis 
by ultraviolet light and 12-O-tetradecanoylphorbol-13-acetate in the 
skin of SKH-1 mice. Cancer Res 1992;52:1162-1170.
37. Bhimani RS, Troll W, Grunberger D, Frenkel K. Inhibition of 
oxidative stress in HeLa cells by chemopreventive agents. Cancer 
Res 1993;53:4528-4533.
38. Mak JC. Potential role of green tea catechins in various disease 
therapies: progress and promise. Clin Exp Pharmacol Physiol 
2012;39:265-273.
39. Singh BN, Shankar S, Srivastava RK. Green tea catechin, 
epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and 
clinical applications. Biochem Pharmacol 2011;82:1807-1821.
40. Smith DM, Daniel KG, Wang Z, Guida WC, Chan TH, Dou 
QP. Docking studies and model development of tea polyphenol 
213Cancer Biol Med Vol 10, No 4 December 2013
proteasome inhibitors: applications to rational drug design. 
Proteins 2004;54:58-70.
41. Ettari R, Bonaccorso C, Micale N, Heindl C, Schirmeister T, 
Calabrò ML, et al. Development of novel peptidomimetics 
containing a vinyl sulfone moiety as proteasome inhibitors. Chem 
Med Chem 2011;6:1228-1237.
42. Lawrence HR, Kazi A, Luo Y, Kendig R, Ge Y, Jain S, et al. 
Synthesis and biological evaluation of naphthoquinone analogs 
as a novel class of proteasome inhibitors. Bioorg Med Chem 
2010;18:5576-5592.
43. Marzaro G, Gandin V, Marzano C, Guiotto A, Chilin A. 
Psoralenquinones as a novel class of proteasome inhibitors: design, 
synthesis and biological evaluation. Chem Med Chem 2011;6:996-
1000.
44. Harding CV, France J, Song R, Farah JM, Chatterjee S, Iqbal 
M, et al. Novel dipeptide aldehydes are proteasome inhibitors 
and block the MHC-I antigen-processing pathway. J Immunol 
1995;155:1767-1775.
45. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, et 
al. Proteasome inhibitors block development of Plasmodium spp. 
Antimicrob Agents Chemother 1998;42:2731-2738.
46. Fang H, Hu Z, Zhou G. Establishment of a GFP-based cellular 
model for screening novel proteasome inhibitors. Sheng Wu Gong 
Cheng Xue Bao 2009;25:452-456.
47. Mujtaba T, Kanwar J, Wan SB, Chan TH, Dou QP. Sensitizing 
human multiple myeloma cells to the proteasome inhibitor 
bortezomib by novel curcumin analogs. Int J Mol Med 
2012;29:102-106.
48. Roginsky AB, Ujiki MB, Ding XZ, Adrian TE. On the potential use 
of flavonoids in the treatment and prevention of pancreatic cancer. 
In Vivo 2005;19:61-67.
49. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, 
Gaur U, et al. Resveratrol inhibits proliferation, induces apoptosis, 
and overcomes chemoresistance through down-regulation of 
STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell 
survival gene products in human multiple myeloma cells. Blood 
2007;109:2293-2302.
50. Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, et al. A 
phase 2 study of SRT501 (resveratrol) with bortezomib for patients 
with relapsed and or refractory multiple myeloma. Br J Haematol 
2013;160:714-717.
51. Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P, et al. Preclinical 
evaluation of the antitumor activity of bortezomib in combination 
with vitamin C or with epigallocatechin gallate, a component of 
green tea. Cancer Chemother Pharmacol 2011;68:1145-1154.
52. Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green 
tea for you? Blood 2009;113:5695-5696.
53. Wickremasinghe RG. Why is CLL refractory to bortezomib? Blood 
2008;112:3540-3541.
Cite this article as: Jia L, Liu FT. Why bortezomib cannot go with ‘green’? 
Cancer Biol Med 2013;10:206-213. doi: 10.7497/j.issn.2095-3941.2013.04.004
